Research Opportunity: ro-cancerimmunologyandimmunotherapy
6/17/2025
Despite advancements in melanoma treatment with immune checkpoint blockade (ICB) and BRAF-targeted therapy, 40-65% of metastatic melanoma patients do not survive beyond five years. An observed 'obesity paradox' shows improved…
6/17/2025
We forge collaborative efforts at the dynamic intersection of biology, chemistry, and medicine, propelling forward the boundaries of scientific exploration. Our work revolves around the development of cutting-edge imaging tools,…
6/17/2025
To treat cancer effectively, great efforts have been devoted to molecularly targeted therapy. While there have been great examples of success, cancer cells often develop drug resistance to evade therapy.…
